Open Science for Children’s Health

M4K Pharma is using open science to revolutionize how affordable new treatments are discovered and developed. Through our Medicines4Kids program, we are aggregating and aligning the work of global academics, foundations and pharma/biotech researchers to advance new cures for childhood diseases not well served by current business models.

M4K Pharma’s first program is the discovery, development and commercialization of an ALK2 enzyme inhibitor which will provide the first therapeutic developed specifically for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG).

In line with M4K Pharma’s open science principles, we are committed to sharing our research data freely in the public domain. Our data is currently available for public viewing in the video recordings of our monthly open scientific updates, which are posted to our blog and also available through our YouTube Channel.

Latest Project Meetings

Latest Blog Posts

Resources
Peter Sampson Joins Agora as VP, Drug Discovery and Development [Press Release]
Peter Sampson Joins Agora as VP, Drug Discovery and Development [Press Release]

M4K Pharma is pleased to announce the appointment of Dr. Peter Sampson as the new Vice President of Drug Discovery and Development for M4K’s parent Canadian charity, Agora Open Science Trust (Agora).

Childhood Cancer Awareness Month
Childhood Cancer Awareness Month

In a piece to mark Childhood Cancer Awareness Month, Dr. Diana Martins Carvalho reflects on the vital support of families who generously donate tissue samples and funds that enable her research into childhood brain tumours.

M4K Team Publishes in J. Med. Chem.
M4K Team Publishes in J. Med. Chem.

In the May and September 2020 issues of the Journal of Medicinal Chemistry, the M4K team and collaborators published two articles on M4K’s open science approach and the chemistry progress to develop the inhibitors for ALK2 as a treatment for Diffuse Intrinsic Pontine Glioma (DIPG).

Hope of New Medicine for Childhood Cancer
Hope of New Medicine for Childhood Cancer

Our collaborator Dr Chris Jones and his fantastic team at The Institute of Cancer Research were profiled in The Observer for their work on DIPG with support from Abbie’s Army.